Problemas jurídicos en torno a los programas de adquisición de la nacionalidad por inversiones
Revista Española de Derecho Internacional · 08.06.2026 · 78 (1) · 13-42
DOI: 10.36151/redi.78.1.1 ↗Kurz gefasst
Fachartikel in der Zeitschrift Revista Española de Derecho Internacional, online erschienen am 08.06.2026. Verfasst von Fernando Arlettaz. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
For several decades, many States have been implementing programmes granting citizenship in exchange for investments. There is no rule of International Law that prohibits States from granting this type of citizenship. The rule established by the International Court of Justice in the Nottebohm case, according to which nationality presupposes the existence of a genuine link between an individual and a State, does not result in the unlawfulness of granting a nationality that does not meet this standard of effectiveness, but at most prevents the invocation of such nationality against other States under certain circumstances. However, in the context of European Union Law, granting nationality in exchange for investments entails a violation of the principle of sincere cooperation, as declared by the Court of Justice of the European Union in the Commission v. Malta case.
Zitieren
APA
Arlettaz, F. (2026). Problemas jurídicos en torno a los programas de adquisición de la nacionalidad por inversiones. Revista Española de Derecho Internacional, 78(1), 13-42. https://doi.org/10.36151/redi.78.1.1
Vancouver
Arlettaz F. Problemas jurídicos en torno a los programas de adquisición de la nacionalidad por inversiones. Revista Española de Derecho Internacional. 2026;78(1):13-42. doi:10.36151/redi.78.1.1
BibTeX
@article{Arlettaz2026,
author = {Arlettaz, Fernando},
title = {Problemas jurídicos en torno a los programas de adquisición de la nacionalidad por inversiones},
journal = {Revista Española de Derecho Internacional},
year = {2026},
volume = {78},
number = {1},
pages = {13--42},
doi = {10.36151/redi.78.1.1}
}
EUVIMED